Studying Gene Expression and Location in Samples From Patients With Brain Tumors
NCT ID: NCT01585389
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10 participants
OBSERVATIONAL
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research studies gene expression and location in samples from patients with brain tumors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Gene Expression in Samples From Younger Patients With Neuroblastoma
NCT01553448
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
NCT01493830
Genetic Analysis of Brain Tumors
NCT00031538
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors
NCT01553175
Biomarkers in Young Patients With Neuroblastoma
NCT01169376
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine the expression and subcellular localization of nei endonuclease VIII-like 3 (NEIL3) in brain tumors.
OUTLINE: Tissue microarray samples are analyzed for NEIL3 expression and subcellular localization by immunohistochemical methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gene expression analysis
genetic linkage analysis
microarray analysis
immunohistochemistry staining method
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tissue microarrays (TMA) samples from the Biopathology Core
* Samples from patients diagnosed with brain tumors
* Progenitor, or blast, cell origin
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Heithem M. El-Hodiri, PhD
Role: PRINCIPAL_INVESTIGATOR
Nationwide Children's Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-ABTR12B3
Identifier Type: OTHER
Identifier Source: secondary_id
ABTR12B3
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000732178
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-00731
Identifier Type: REGISTRY
Identifier Source: secondary_id
ABTR12B3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.